VLPbio develops novel veterinary vaccines using a proprietary platform based on chimeric pseudoviral particles (Ch‑VLPs) that expose specific antigens to generate immune responses. Its platform is protected by a strong portfolio of patents and is designed to be safe by not incorporating infectious material, enabling DIVA (differentiate infected from vaccinated animals) capability. The company reports promising results across indications in the poultry, bovine and swine sectors, demonstrating the platform's broad applicability. VLPbio emphasizes a solid strategic plan and an experienced team as key assets for growth. The recent financing is intended to expand and reinforce current development programs and to carry out regulatory trials needed prior to commercialization.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2018